Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 01530 3SBIO > Company Profile
01530 3SBIO
8.110
-0.040-0.49%
Symbol
01530
Company Name
3SBIO
ISIN
KYG8875G1029
Listing Date
06/11/2015
Establishment Date
08/09/2006
Registration
Cayman Islands
Chairman
Jing Lou
Secretary
Shaojuan Li
Audit Institution
Ernst & Young accounting firm
Company Category
Overseas registration of Mainland Individuals control
Registered Office
Cricket Square,Hutchins Drive PO Box 2681 Grand Cayman,KY1-1111 Cayman Islands
Head Office and Principal Place of Business
5 / F, Manulife Plaza, 348 Kwun Tong Road, Kowloon, Hong Kong
Fiscal Year Ends
12-31
Employees
5160
Market
Hong Kong motherboard
Phone
+86 24 25386000
Fax
+86 24 25811821
Business
Sansheng Pharmaceutical is an investment holding company mainly engaged in the development, production, marketing and sales of pharmaceutical products. The company's main products include recombinant human thrombopoietin products, tumor necrosis factor-α inhibitors and recombinant human erythropoietin. The products are sold under the brands of Tebio, Yisep, iBio, and Cyber. The company sells products in the domestic market and overseas markets such as Sri Lanka, the Dominican Republic and Thailand. The company's subsidiaries include Jisi Co., Ltd., Hong Kong Sansheng Medical Co., Ltd. And Shenyang Sansheng Pharmaceutical Co., Ltd. The company is also engaged in project management and consulting through its subsidiaries.
Profile
Sansheng Pharmaceutical (the "Company" or "Sansheng Pharmaceutical", together with its subsidiaries collectively referred to as the "Group") is a leading biotechnology company in the people's Republic of China (the "PRC"). As a pioneer in the biotechnology industry in China, the Group has rich experience in R & D, production and marketing of biomedical products. The Group's core products include Tabio, Recombinant Human Erythropoietin ("rhEPO") products iBio and Cyber, and Yisaipu Mendi. Tabio is the only commercial recombinant human thrombopoietin ("rhTPO") product in the world. In the first half of 2022, Terbiao had 66.0% of the market for thrombocytopenia treatment in mainland China by sales, according to IQVIA1. With two rhEPO products, the Group has been the market leader in rhEPO in mainland China for two decades, with a total share of 44.1% in the first half of 2022. Yisepu is a tumor necrosis factor ("TNF") α inhibitor product, occupying 28.2% of the TNF α market in mainland China in the first half of 2022. In the first half of 2022, Mandy had a dominant 71.9% market share in mainland China's minoxidil tincture market by sales, according to the China Pharmaceutical Association. The Group also increases its products through internal research and development ("R & D") and a number of external strategies to expand the field of treatment. At the same time, the Group has increased its revenue scale through strategic bureau contract development and production operations ("CDMO") business, which has been in operation since December 2021 and its business scale in mainland China has increased rapidly. On June 30, 2022, of the 33 products under research and development by the Group, 26 were developed as innovative drugs in mainland China. Among the 33 products under study, 18 were antibodies, 7 were other biological products and 8 were small molecular drugs. The Group has 11 oncology products in progress; 13 products in progress targeting autoimmune diseases (including rheumatoid arthritis ("RA")), and other diseases, including obstinate gout and eye diseases (such as age-related macular degeneration ("AMD"); 9 nephrology products in progress; and 1 dermatology product in progress. The industry in which the Group operates is very attractive. Biotechnology has brought about great changes in the pharmaceutical industry by meeting unmet medical needs and providing innovative treatments for a wide range of human diseases. In mainland China, the biopharmaceutical industry is strongly supported by the government and recognized by the State Council as an important strategic emerging industry. Strong government support and the growing adoption of biopharmaceutical products by doctors in mainland China have contributed to the strong growth of the industry. The Group is expanding around the world. Outside the mainland of China, Terbio has been approved by nine countries; iBio has been approved by 23 countries; and Yisep has been approved by 15 countries. In the long run, the Group's goal is to market its products in developed countries. The Group also cooperates with international partners to develop and market the Group's products under development, such as pegsiticase and monoclonal antibodies against programmed death receptor 1 ("PD-1"). The Group aims to focus on research and development to provide innovative treatments for patients in mainland China and around the world. As at 30 June 2022, the Group had operating facilities in Shenyang, Shanghai, Hangzhou and Shenzhen (all located in mainland China) and Cuomo in Italy with a staff of 5160. The Group's pharmaceutical products are promoted and sold in all provinces, autonomous regions and municipalities directly under the Central Government in mainland China and in a number of overseas countries and regions. During the six months ended 30 June 2022 (the "reporting period"), the Group's national distribution network sold the Group's products to more than 7500 hospitals and medical institutions in mainland China.
Company Overview
Sansheng Pharmaceutical (the "Company" or "Sansheng Pharmaceutical", together with its subsidiaries collectively referred to as the "Group") is a leading biotechnology company in the people's Republic of China (the "PRC"). As a pioneer in the biotechnology industry in China, the Group has rich experience in R & D, production and marketing of biomedical products. The Group's core products include Tabio, Recombinant Human Erythropoietin ("rhEPO") products iBio and Cyber, and Yisaipu Mendi. Tabio is the only commercial recombinant human thrombopoietin ("rhTPO") product in the world. In the first half of 2022, Terbiao had 66.0% of the market for thrombocytopenia treatment in mainland China by sales, according to IQVIA1. With two rhEPO products, the Group has been the market leader in rhEPO in mainland China for two decades, with a total share of 44.1% in the first half of 2022. Yisepu is a tumor necrosis factor ("TNF") α inhibitor product, occupying 28.2% of the TNF α market in mainland China in the first half of 2022. In the first half of 2022, Mandy had a dominant 71.9% market share in mainland China's minoxidil tincture market by sales, according to the China Pharmaceutical Association. The Group also increases its products through internal research and development ("R & D") and a number of external strategies to expand the field of treatment. At the same time, the Group has increased its revenue scale through strategic bureau contract development and production operations ("CDMO") business, which has been in operation since December 2021 and its business scale in mainland China has increased rapidly. On June 30, 2022, of the 33 products under research and development by the Group, 26 were developed as innovative drugs in mainland China. Among the 33 products under study, 18 were antibodies, 7 were other biological products and 8 were small molecular drugs. The Group has 11 oncology products in progress; 13 products in progress targeting autoimmune diseases (including rheumatoid arthritis ("RA")), and other diseases, including obstinate gout and eye diseases (such as age-related macular degeneration ("AMD"); 9 nephrology products in progress; and 1 dermatology product in progress. The industry in which the Group operates is very attractive. Biotechnology has brought about great changes in the pharmaceutical industry by meeting unmet medical needs and providing innovative treatments for a wide range of human diseases. In mainland China, the biopharmaceutical industry is strongly supported by the government and recognized by the State Council as an important strategic emerging industry. Strong government support and the growing adoption of biopharmaceutical products by doctors in mainland China have contributed to the strong growth of the industry. The Group is expanding around the world. Outside the mainland of China, Terbio has been approved by nine countries; iBio has been approved by 23 countries; and Yisep has been approved by 15 countries. In the long run, the Group's goal is to market its products in developed countries. The Group also cooperates with international partners to develop and market the Group's products under development, such as pegsiticase and monoclonal antibodies against programmed death receptor 1 ("PD-1"). The Group aims to focus on research and development to provide innovative treatments for patients in mainland China and around the world. As at 30 June 2022, the Group had operating facilities in Shenyang, Shanghai, Hangzhou and Shenzhen (all located in mainland China) and Cuomo in Italy with a staff of 5160. The Group's pharmaceutical products are promoted and sold in all provinces, autonomous regions and municipalities directly under the Central Government in mainland China and in a number of overseas countries and regions. During the six months ended 30 June 2022 (the "reporting period"), the Group's national distribution network sold the Group's products to more than 7500 hospitals and medical institutions in mainland China.
CEO: Jing Lou
Market: Hong Kong motherboard
Listing Date: 06/11/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist